The dismal results of the AstraZeneca vaccine trial, released on Sunday, are a "reality check", says Wits professor Shabir Madhi, after hopes were raised last year when other vaccines proved to be 95% effective against Covid-19.

Madhi was speaking after it emerged on Sunday that the AstraZeneca-Oxford vaccine did not prevent mild disease in a group of young and healthy people. This was due to a new variant 501Y.V2, first detected in SA. The trials measured "disease" as a single symptom of cough, fever or sore throat...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now